Tag - Vital Therapies

Vital Therapies’ (NASDAQ:VTL) VTL-308 Phase 3 trial to evaluate its cell-based therapy, ELAD, in subjects with severe alcoholic hepatitis has reached its enrollment target of 150 subjects. Subjects in VTL-308 were...